



Europäische Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 782 855 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

09.07.1997 Bulletin 1997/28

(21) Application number: 95933625.6

(22) Date of filing: 05.10.1995

(51) Int. Cl.<sup>6</sup>: **A61K 31/18**, A61K 9/10,

A61K 9/06, A61K 47/14,

A61K 47/10, A61K 47/18,

A61K 47/22

(86) International application number:

PCT/JP95/02045

(87) International publication number:

WO 96/11002 (18.04.1996 Gazette 1996/17)

(84) Designated Contracting States:

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE

(30) Priority: 05.10.1994 JP 268293/94

(71) Applicant: Helsinn Healthcare S.A.  
6915 Pambio Noranco (CH)

(72) Inventors:

- MIYATA, Satoru,  
Hisamitsu Phar. Co., Inc.  
Tosu-shi, Saga 841 (JP)

- TANIGUCHI, Yasuaki,  
Hisamitsu Pharm. Co., Inc.  
Tosu-shi, Saga 841 (JP)

- MASUDA, Kenji,  
Hisamitsu Phar. Co., Inc.  
Tosu-shi, Saga 841 (JP)

- KAWAMURA, Yoichi,  
Hisamitsu Phar. Co., Inc.  
Tosu-shi, Saga 841 (JP)

(74) Representative: Minoja, Fabrizio  
Studio Consulenza Brevettuale,  
Via Rossini, 8  
20122 Milano (IT)

(54) **ANTIINFLAMMATORY AGENT FOR EXTERNAL USE**

(57) An antiinflammatory agent for external use,  
containing nimesulide as the active ingredient dis-  
persed in the base component and being well absorba-  
ble, safe and discoloration-free.

*low surfact*

EP 0 782 855 A1

**Description**Field of the Industrial Use

5 The present invention relates to an antiinflammatory agent for external use comprising nimesulide as an active ingredient. In particular, the present invention relates to an antiinflammatory agent for external use comprising nimesulide as an active ingredient and a base component wherein the nimesulide is mixed in a dispersed state in the base component, as well as to a process for preparing the same.

10 Prior Art

Non-steroidal antiinflammatory preparations have a disadvantage that, when orally administered, they cause gastrointestinal tract disorders. In order to avoid this disadvantage, various studies have been made to develop antiinflammatory agent for external use and several commercial products have been provided for clinical use. However, the antiinflammatory agent for external use hitherto developed have insufficient clinical effects even if they show effects in the basic tests.

Nimesulide (4-nitro-2-phenoxyethanesulfonamide), which is one of the non-steroidal antiinflammatory agents, was first synthesized by Riker Co. in the United States and then developed as an oral preparation in Europe by Helsinn Co. in Switzerland. Being different from the conventional acidic antiinflammatory agents, it is known that nimesulide selectively inhibits PGE<sub>2</sub> (COX<sub>2</sub>) and this is a new type pharmaceutical agent expected to take effects in clinical use.

As the prior art regarding nimesulide, the substance patent described in U.S. Patent No. 3,480,597 and process patents described in the examined Japanese patent publication (Kokoku) Sho-58-35989, the examined Japanese patent publication (Kokoku) Sho-58-50984 and the examined Japanese patent publication (Kokoku) Sho-59-44311 may be cited. However, these prior art references do not have descriptions or working examples regarding the actual pharmaceutical preparations, although they mention dosage forms such as capsule, cream, gel, tape, and the like.

In addition, the laid-open Japanese patent application (Kohyo) Hei-6-502842 based on the international patent application may be cited as a reference relating to the pharmaceutical preparation of nimesulide. This patent is to prepare an inclusion compound of nimesulide with cyclodextrin to make nimesulide water-soluble so as to increase water-solubility and to increase absorption of nimesulide in the gastrointestinal tract. Therefore, its object is not the external use. Thus, no reference is known which illustratively discloses use of nimesulide as an external preparation, and no case is known with respect to the actual external use of nimesulide in a particular dosage form.

It would be due to the fact that, although nimesulide has pharmacological effects equal to or higher than those of indomethacin which is regarded as a potent antiinflammatory agent, it has several unsolved problems when topically applied as an external preparation. That is, (1) nimesulide is hardly soluble and is not easily dissolved in water and various organic solvents. (2) A solvent which has strong solubilizing ability should be mixed to dissolve nimesulide, causing problems such as skin irritation, chapped skin, itch, and flare. (3) Even if nimesulide is dissolved, the resulting pharmaceutical preparation becomes deep yellow and thus its appearance becomes bad. (4) The pharmaceutical preparation applied soils clothes that contact the preparation.

Thus, there is a situation that the attempt to use nimesulide as the external preparation was abandoned.

Problems to be Solved by the Invention

The object of the present invention is to obtain an antiinflammatory agent for external use including nimesulide for topical use, which is a nimesulide external preparation showing excellent absorption and having no problem in coloring and skin safety.

Means for Solving the Problems

As a result of extensive studies taking the above-described disadvantages of nimesulide as an external preparation into consideration, the present inventors found that the above-described disadvantages are all solved when nimesulide is mixed in a dispersed state in a base component, and completed the present invention. That is, when nimesulide is mixed in a dispersed state in a base component, it surprisingly shows pharmacological effects equal to or higher than those of the pharmaceutical preparation in which nimesulide is mixed in a dissolved form. In addition, the amount of a solubilizing agent can be reduced and therefore the skin safety is improved. Furthermore, it is proved that the coloring of the pharmaceutical preparation does not occur, which is different from the completely dissolved-type pharmaceutical preparation. That is, all the above-described problems as the external preparation can be solved.

In particular, the object of the present invention is achieved by mixing nimesulide as an active ingredient in a dispersed state in a base component which comprises an oily substance, a nonionic surface active agent, a basic substance, water and/or an absorption enhancer. More particularly, 0.1 to 5% by weight of nimesulide as an active

ingredient in a form of fine particles is dispersed and mixed in the base component which further comprises a hydrophilic polymer or a white petrolatum to prepare an external preparation such as cream or ointment.

Nimesulide as an active ingredient may be used in any form as long as it can be made into a dispersed state in a base component. In view of the easiness in grinding of the particles to be dispersed and the cost, the mean particle diameter of nimesulide is preferably 0.01  $\mu\text{m}$  or more. On the other hand, in view of the transdermal absorbability and feeling on application (rough feeling), it is preferably 75  $\mu\text{m}$  or less, i.e., the particle sizes that pass through a 200-mesh sieve, and more preferably from 0.5 to 50  $\mu\text{m}$ , and further preferably from 1 to 30  $\mu\text{m}$ .

The antiinflammatory agent for external use of the present invention may be prepared as follows. For example, the cream agent is prepared by mixing and stirring an oil phase of heat-melted oil components and an aqueous phase in which water-soluble components have been dissolved; adding nimesulide in a form of fine particles; and further carrying out stirring and cooling. The ointment is prepared by adding nimesulide in a form of fine particles into the heat-melted oil components with stirring and cooling, and further carrying out stirring and cooling.

The pH of the pharmaceutical preparation may desirably be controlled from 4 to 8, more preferably from 5 to 7, in view of the skin irritation and the transdermal absorbability.

Examples of the base to prepare the antiinflammatory agent for external use of the present invention include a so-called gel cream comprising a hydrophilic polymer, an oily substance, a nonionic surface active agent, a basic substance, and water; a vanishing cream produced from a higher alcohol, a hydrocarbon, a fatty acid ester, a polyhydric alcohol, a base, an antiseptic, water, and the like; a hydrophilic ointment or an absorptive ointment cream according to *The Japanese Pharmacopeia* produced from a white petrolatum, a surface active agent, a higher alcohol, a hydrocarbon, a fatty acid ester, a polyhydric alcohol, an antiseptic, water, and the like; and the FAPG base comprising a higher alcohol, polyhydric alcohol, and the like. As the prescription for the cream agent, a pharmaceutical preparation obtained by mixing 0.1 to 5% by weight of nimesulide in a so-called gel cream base comprising 0.2 to 3% by weight of a hydrophilic polymer, 2 to 20% by weight of an oily substance, 0.5 to 7% by weight of a nonionic surface active agent, 0.01 to 5% by weight of a basic substance, and 50 to 90% by weight of water is the most preferable from the viewpoint of the transdermal absorption. As the prescription for the ointment preparation, a pharmaceutical preparation obtained by mixing 0.1 to 5% by weight of nimesulide in a petrolatum ointment comprising 35 to 80% by weight of a white petrolatum, 2 to 20% by weight of an oily substance, and 0.5 to 7% by weight of a nonionic surface active agent is the most preferable.

Then, the base components of the present invention are described in further detail.

Examples of the hydrophilic polymer include carboxyvinyl polymers (CARBOPOL 940, 941 manufactured by B.F. Goodrich Chemical Co., HIBISWAKO 104, 105, manufactured by Wako Pure Chemical Industries, Ltd., and the like), hydroxypropylcellulose (HPC-L, HPC-M manufactured by Nippon Soda Co., Ltd., and the like), polyoxyethylenepolyoxypropylene block polymer (Lutrol F68 manufactured by BASF Co., and the like). These hydrophilic polymers may be used alone or as a mixture of two or more and mixed preferably in an amount of from 0.2 to 3% by weight, more preferably, from 0.5 to 2% by weight in view of the viscosity and stickiness of the cream.

Examples of the oily substance include fatty acid esters such as diisopropyl adipate, diisopropyl sebacate, diethyl sebacate, middle-length fatty acid triglycerides, middle-length fatty acid propylene glycols, isopropyl myristate, and the like; fatty acids such as stearic acid, oleic acid, myristic acid, and the like; higher alcohols such as cetanol, stearyl alcohol, cetostearyl alcohol, oleyl alcohol, behenyl alcohol, and the like; hydrocarbons such as white petrolatum, liquid paraffin, squalane, and the like; plant oils and fats such as olive oil, hohoba oil, castor oil, and the like; and other oily substances such as crotamiton, benzyl alcohol, and the like. In the case of the cream preparation, the oily substance is mixed in an amount of from 2 to 20% by weight, preferably from 5 to 15% by weight, in view of the spreadability of cream, transdermal absorption, stickiness, shining, and instability in production of preparations (e.g., liquid separation), and the like. In the case of the ointment preparation, it is mixed in an amount of from 2 to 20% by weight, preferably from 3 to 7% by weight.

Examples of the surface active agent include sorbitan fatty acid esters such as sorbitan monostearate, sorbitan sesquisteate, and the like; glycerol fatty acid esters such as glyceryl monostearate, diglyceryl monooleate, and the like; polyoxyethylenesorbitan fatty acid esters such as polyoxyethylene(20)sorbitan monostearate, polyoxyethylene(20)sorbitan monooleate, and the like; polyethylene glycol fatty acid esters such as polyoxyethylene(10) monostearate, polyoxyethylene(10) monolaurate, and the like; polyoxyethylene alkyl ethers such as polyoxyethylene(9) lauryl ether, polyoxyethylene(23) cetyl ether, and the like; polyoxyethylene alkylphenyl ethers such as polyoxyethylene(10) nonylphenyl ether, polyoxyethylene(10) octylphenyl ether, and the like; and polyoxyethylene hydrogenated castor oil such as polyoxyethylene(10) hydrogenated castor oil, polyoxyethylene(60) hydrogenated castor oil, and the like. These surface active agents may be used alone or as a mixture of two or more and mixed in an amount of from 0.5 to 7% by weight, preferably, from 1 to 5% by weight.

Examples of the basic substance include inorganic or organic bases such as potassium hydroxide, sodium hydroxide, triethanolamine, diisopropanolamine, monoethanolamine, and the like, and organic bases are preferable from the viewpoint of the transdermal absorption. These basic substance may be mixed in an amount of from 0.01 to 5% by weight, preferably from 0.1 to 2% by weight.

In addition, in order to enhance the transdermal absorption of nimesulide, the absorption enhancer may be mixed in the above-described pharmaceutical preparation depending on the type of the pharmaceutical prescription. Examples of the absorption enhance include organic bases, crotamiton, middle-length fatty acid esters, 1-menthol, benzyl alcohol, and the like. The organic base facilitates the release of nimesulide from the base since it makes nimesulide water-soluble by forming a salt with nimesulide. Examples of the organic base include diisopropanolamine, meglumine, triethanolamine, and 1-(2-hydroxyethyl)pyrrolidine, and diisopropanolamine and 1-(2-hydroxyethyl)pyrrolidine are the most preferable. The absorption enhancer is mixed in an amount of from 0.1 to 20% by weight, preferably from 0.2 to 10% by weight, alone or as a mixture of two or more.

The above-described basic substance and the organic base as an absorption enhancer act also as a pH controlling agent of the preparation. That is, when pH of the pharmaceutical preparation is too low (e.g., 3 or less), the high acidity makes skin irritation strong. When pH is too high (e.g., 9 or more), the transdermal absorbability of the medical agent is reduced, skin irritation becomes strong, and the pharmaceutical preparation colors yellow. Accordingly, the pH of the pharmaceutical preparation is controlled preferably in the range of from 4 to 8 by the amount of the above-described basic substance or the absorption enhancer to be mixed.

In addition to the above-described components, animal oils and fats, waxes, hydrocarbons, antiseptics, wetting agents, and the like may be added and mixed. Examples of the animal oil and fat include beef tallow, pork tallow, horse oil, and the like. Examples of the wax include microcrystalline wax, montan wax, bees wax, and the like. Examples of the hydrocarbon include paraffin, ceresine, and the like. Examples of the antiseptic include methylparaben, propylparaben, butylparaben, and the like. Examples of the wetting agent include polyhydric alcohols such as glycerol, 1,3-butylene glycol, propylene glycol, dipropylene glycol, and the like. These additives may be the mixed in amounts generally employed for cream and ointment preparations.

### Examples

The present invention is illustrated in greater detail with reference to the following Examples.

#### Example 1

	Component	% by weight
(1)	Nimesulide (Particle Diameter: 5 to 20 $\mu\text{m}$ )	3
(2)	Carboxyvinyl Polymer	1
(3)	Diisopropyl Sebacate	5
(4)	Isopropyl Myristate	10
(5)	Crotamiton	3
(6)	Polyoxyethylene(20)sorbitan Monostearate	5
(7)	Methylparaben	0.1
(8)	Propylparaben	0.1
(9)	Diisopropanolamine	0.5
(10)	Purified Water	72.3
		100.0

The components (3), (4), (5), (6), and (8) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (7) in about 90% of the component (10) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (9) in the remaining component (10) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide.

## Example 2

	Component	% by weight
(1)	Nimesulide (Particle Diameter: 20 to 40 $\mu\text{m}$ )	3
(2)	Carboxyvinyl Polymer	1
(3)	Diisopropyl Sebacate	5
(4)	Isopropyl Myristate	10
(5)	Crotamiton	3
(6)	Polyoxyethylene(20)sorbitan Monostearate	5
(7)	Methylparaben	0.1
(8)	Propylparaben	0.1
(9)	Diisopropanolamine	0.5
(10)	Purified Water	72.3
		100.0

The components (3), (4), (5), (6), and (8) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (7) in about 90% of the component (10) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (9) in the remaining component (10) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide.

## Example 3

	Component	% by weight
(1)	Nimesulide (Particle Diameter: 5 to 20 $\mu\text{m}$ )	3
(2)	Carboxyvinyl Polymer	1
(3)	Diethyl Sebacate	5
(4)	Middle-length Fatty Acid Triglyceride	8
(5)	Crotamiton	3
(6)	Polyoxyethylene(20)sorbitan Monostearate	5
(7)	Methylparaben	0.1
(8)	Propylparaben	0.1
(9)	1-(2-Hydroxyethyl)pyrrolidine	0.5
(10)	Purified Water	74.3
		100.0

The components (3), (4), (5), (6), and (8) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (7) in about 90% of the component (10) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by

dissolving the component (9) in the remaining component (10) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide.

#### Example 4

	Component	% by weight
(1)	Nimesulide (Particle Diameter: 5 to 20 $\mu\text{m}$ )	5
(2)	Carboxyvinyl Polymer	1
(3)	Diethyl Sebacate	5
(4)	Middle-length Fatty Acid Triglyceride	8
(5)	Crotamiton	3
(6)	Polyoxyethylene(20)sorbitan Monostearate	5
(7)	Methylparaben	0.1
(8)	Propylparaben	0.1
(9)	1-(2-Hydroxyethyl)pyrrolidine	0.5
(10)	Purified Water	72.3
		100.0

The components (3), (4), (5), (6), and (8) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (7) in about 90% of the component (10) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (9) in the remaining component (10) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide.

#### Example 5

	Component	% by weight
(1)	Nimesulide (Particle Diameter: 0.5 to 10 $\mu\text{m}$ )	3
(2)	Carboxyvinyl Polymer	1
(3)	Diisopropyl Adipate	5
(4)	Isopropyl Myristate	10
(5)	1-Menthol	2
(6)	Polyoxyethylene(20)sorbitan Monostearate	5
(7)	Methylparaben	0.1
(8)	Propylparaben	0.1
(9)	Diisopropanolamine	0.5
(10)	Purified Water	73.3
		100.0

The components (3), (4), (5), (6), and (8) were melted by heating at 75°C. A solution which had been separately

prepared by dissolving the component (7) in about 90% of the component (10) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (9) in the remaining component (10) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide.

#### Example 6

	Component	% by weight
(1)	Nimesulide (Particle Diameter: 0.5 to 10 $\mu\text{m}$ )	0.5
(2)	Stearic Acid	5
(3)	Diisopropyl Adipate	3
(4)	Cetanol	5
(5)	Middle-length Fatty Acid Triglyceride	7
(6)	Polyoxyethylene(23) Cetyl Ether	3
(7)	Sorbitan Monostearate	1
(8)	1,3-Butylene Glycol	5
(9)	Diisopropanolamine	1
(10)	Sodium Benzoate	0.1
(11)	Purified Water	69.4
		100.0

The components (2), (3), (4), (5), (6), and (7) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the components (8), (9), and (10) in the component (11) at 75°C was added, and the mixture was stirred to effect emulsification. The component (1) was gradually added at 50°C or lower, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide.

#### Example 7

	Component	% by weight
(1)	Nimesulide (Particle Diameter: 0.5 to 10 $\mu\text{m}$ )	3
(2)	Crotamiton	3
(3)	Diethyl Sebacate	5
(4)	Microcrystalline Wax	10
(5)	Middle-length Fatty Acid Triglyceride	7
(6)	Propylene Glycol Fatty Acid Ester	10
(7)	Behenyl Alcohol	4
(8)	Diisopropanolamine	0.2
(9)	Dipropylene glycol	7
(10)	Propylene Glycol Monostearate	7
(11)	White Petrolatum	43.8
		100.0

# EP 0 782 855 A1

The components (2), (3), (4), (5), (6), (7), (8), (9), (10), and (11) were melted by heating at 80°C. The component (1) was gradually added at 50°C and dispersed by stirring to obtain an antiinflammatory ointment preparation containing nimesulide.

- 5 Example 8 (A dispersed-type cream preparation in which the active ingredient has the particle diameter of 76 to 180 μm)

10		Component	% by weight
	(1)	Nimesulide (Particle Diameter: 75 to 180 μm)	3
	(2)	Carboxyvinyl Polymer	1
15	(3)	Isopropyl Myristate	15
	(4)	Polyoxyethylene(20)sorbitan Monostearate	5
	(5)	Methylparaben	0.1
	(6)	Propylparaben	0.1
20	(7)	Propylene Glycol	3
	(8)	Diethanolamine	0.5
	(9)	Purified Water	72.3
25			100.0

The components (3), (4), and (6) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the component (6) and (7) in about 90% of the component (9) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred. Then, the component (1) was gradually added and dispersed by stirring. Then, a solution which had been prepared by dissolving the component (8) in the remaining component (9) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide.

- 35 Reference Example (A cream preparation in which the active ingredient is dissolved)

40		Component	% by weight
	(1)	Nimesulide	3
	(2)	Carboxyvinyl Polymer	1
	(3)	Isopropyl Myristate	15
45	(4)	Polyoxyethylene(20)sorbitan Monostearate	5
	(5)	Methylparaben	0.1
	(6)	Propylparaben	0.1
	(7)	1,3-Butylene Glycol	3
50	(8)	Diethanolamine	6
	(9)	Purified Water	66.8
55			100.0

The components (3), (4), and (6) were melted by heating at 75°C. A solution which had been separately prepared by dissolving the components (5) and (7) in about 90% of the component (9) at 75°C was added, and the mixture was stirred to effect emulsification. The component (2) was gradually added at 50°C and the mixture was thoroughly stirred



to dissolve the component (2). Then, the component (1) was gradually added and mixed by stirring. Then, a solution which had been prepared by dissolving the component (8) in the remaining component (9) was added, and the mixture was stirred until the mixture became homogenous to obtain an antiinflammatory cream preparation containing nimesulide.

#### Test Example 1: Suppression test of carrageenin-induced rat foot edema

The antiinflammatory activity of the cream preparations of Examples 1, 2, 5, 7, and 8 and Reference Example as well as a commercially available indomethacin-containing cream preparation were examined based on the suppression of carrageenin-induced rat foot edema.

#### Test Method

The test substance was applied on a right foot sole of male Wister rats each weighing 132 to 150 g, and the right foot sole was fixed by covering with wrapping film. When the drug was applied, the animal was shackled with a plastic neck shackle and put into an individual cage in order to avoid oral ingestion of the drug. After 4 hours from the application of the drug, the drug was completely removed with absorbent cotton containing slightly warm water. Immediately, a physiological saline containing 1% carrageenin (0.1 ml) was subcutaneously injected at foot sole. After 3 hours, the foot volume was measured, and the edematization ratio was calculated based on the foot volume before injection of prophlogistic substance. The test results are shown in Table 1.

Table 1

Sample (administered amount: 100 mg/site)	Number of animals	Edematization ratio (%) (after 3 hours)
Control	8	77.6
Cream preparation of Example 1	8	38.9
Cream preparation of Example 2	8	35.1
Cream preparation of Example 5	8	45.6
Cream preparation of Example 7	8	50.6
Cream preparation of Example 8	8	64.6
Cream preparation of Reference Example	8	53.1
Commercially available indomethacin cream preparation	8	68.6

From the results in Table 1, it is clear that the pharmaceutical preparations of Examples 1, 2, 5, 7, and 8 showed superior antiinflammatory effect in comparison with the commercially available indomethacin cream preparation, which is equal or higher even in comparison with the cream preparation of Reference Example containing nimesulide in a dissolved state.

#### Test Example 2: Coloring test

The cream preparations of the present invention and the cream preparation of the Reference Example were prepared and spread on a cotton cloth, and the degree of coloring was observed. The test results are shown in Table 2.

Table 2

Sample	Appearance at the time of preparation	Coloring of cloth
Cream preparation of Example 1	Slightly yellowish white cream	Almost no coloring
Cream preparation of Example 2	Slightly yellowish white cream	Almost no coloring
Cream preparation of Reference Example	Yellow cream	Colored yellow

As is clear from Table 2, the cloth was colored in the case of the cream preparation of Reference Example containing nimesulide in a dissolved state but the cream preparations of Examples 1 and 2 according to the present invention showed almost no coloring.

## 5 Effect of the Invention

The antiinflammatory agent for external use of the present invention in which nimesulide is mixed in a dispersed state has pharmacological effects equal to or higher than those of the dissolved-type preparation, has no skin irritation, is safe, and does not soil the skin and clothes since it is not colored. Accordingly, the present invention is extremely useful as an agent in the field of dermatology for treating eczema, dermatitis, and the like, and as an antiinflammatory external preparation in the field of orthosis for treating chronic articular rheumatism, osteoarthritis, shoulder joint periarthritis, peritendinitis, myalgia, and tumentia and pain after injury.

## Claims

1. An antiinflammatory agent for external use comprising nimesulide as an active ingredient and a base component, wherein said nimesulide is mixed in a dispersed state in said base component.
2. The antiinflammatory agent for external use as claimed in claim 1, wherein nimesulide is mixed in an amount of from 0.1 to 5% by weight.
3. The antiinflammatory agent for external use as claimed in claim 1, which has pH of from 4 to 8.
4. The antiinflammatory agent for external use as claimed in claim 1, wherein said base component comprises a hydrophilic polymer, a white petrolatum, an oily substance, a nonionic surface active agent, water, a basic substance and/or an absorption enhancer.
5. The antiinflammatory agent for external use as claimed in claim 4, wherein said absorption enhancer is an organic base, crotonon, a middle-length fatty acid ester, 1-menthol, and/or benzyl alcohol.
6. The antiinflammatory agent for external use as claimed in claim 5, wherein said organic base is diisopropylamine, meglumine, triethanolamine, and/or 1-(2-hydroxyethyl)pyrrolidine.
7. The antiinflammatory agent for external use as claimed in any of claims 1 to 6, wherein the dosage form is a cream preparation.
8. The antiinflammatory agent for external use as claimed in claim 7, wherein nimesulide in an amount of 0.1 to 5% by weight is mixed in a gel-like cream base comprising a hydrophilic polymer in an amount of from 0.2 to 3% by weight, an oily substance in an amount of from 2 to 20% by weight, a nonionic surface active agent in an amount of from 0.5 to 7% by weight, a basic substance in an amount of from 0.01 to 5% by weight, and water in an amount of from 50 to 90% by weight.
9. The antiinflammatory agent for external use as claimed in any of claims 1 to 7, wherein the dosage form is an ointment preparation.
10. The antiinflammatory agent for external use as claimed in claim 9, wherein nimesulide in an amount of 0.1 to 5% by weight is mixed in a petrolatum ointment base component comprising a white petrolatum in an amount of from 35 to 80% by weight, an oily substance in an amount of from 2 to 20% by weight, and a nonionic surface active agent in an amount of from 0.5 to 7% by weight.
11. A process for producing an antiinflammatory agent for external use, which comprises gradually adding nimesulide as an active ingredient in a form of fine particles into a base component, and dispersing nimesulide by stirring.
12. The process as claimed in claim 11, wherein an oil component melted by heating is used as the base component.
13. The process as claimed in claim 11, wherein an oil phase of heat-melted oil components and an aqueous phase in which water-soluble components have been dissolved are mixed by stirring and used as a base component.
14. The process as claimed in any of claims 11 to 13, wherein nimesulide having a mean particle diameter of from 0.01

to 75- $\mu\text{m}$  is used as the nimesulide in a form of fine particles.

5

10

15

20

25

30

35

40

45

50

55

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/JP95/02045

A. CLASSIFICATION OF SUBJECT MATTER Int. C1<sup>6</sup> A61K31/18, A61K9/10, A61K9/06, A61K47/14, A61K47/10, A61K47/18, A61K47/22

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. C1<sup>6</sup> A61K31/18, A61K9/10, A61K9/06, A61K47/14, A61K47/10, A61K47/18, A61K47/22

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, 6-502842, A (Boehringer Ingelheim Italia S.p.A.), March 31, 1994 (31. 03. 94) & WO, 9117774, A1	1-14

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"A" document member of the same patent family

Date of the actual completion of the international search  
December 4, 1995 (04. 12. 95)

Date of mailing of the international search report  
December 26, 1995 (26. 12. 95)

Name and mailing address of the ISA/  
Japanese Patent Office  
Facsimile No.

Authorized officer  
Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)